Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ IKZF3 Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA577190
Description
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
This gene encodes a member of the Ikaros family of zinc-finger proteins. Three members of this protein family (Ikaros, Aiolos and Helios) are hematopoietic-specific transcription factors involved in the regulation of lymphocyte development. This gene product is a transcription factor that is important in the regulation of B lymphocyte proliferation and differentiation. Both Ikaros and Aiolos can participate in chromatin remodeling. Regulation of gene expression in B lymphocytes by Aiolos is complex as it appears to require the sequential formation of Ikaros homodimers, Ikaros/Aiolos heterodimers, and Aiolos homodimers. At least six alternative transcripts encoding different isoforms have been described.
Specifications
IKZF3 | |
Polyclonal | |
Unconjugated | |
Ikzf3 | |
5830411O07Rik; AIO; AIOLOS; IKAROS family zinc finger 3; IKAROS family zinc finger 3 (Aiolos); ikaros family zinc finger protein 3; Ikzf3; Zfpn1a3; zinc finger DNA binding protein Aiolos; zinc finger protein Aiolos; zinc finger protein, subfamily 1A, 3 (Aiolos); Znfn1a3 | |
Rabbit | |
Antigen Affinity Chromatography | |
RUO | |
22780, 22806 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.2 | |
O08900, Q9UKT9 | |
Ikzf3 | |
Recombinant full length Human IKZF3. | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction